J Ricardo Carhuapoma1, Ryan J Barrett, Penelope M Keyl, Daniel F Hanley, Robert R Johnson. 1. Division of Neurosciences Critical Care, Departments of Neurology, Neurosurgery and Anesthesiology & Critical Care Medicine, The Johns Hopkins Hospital, 600 North Wolfe Street/Meyer 8-140, Baltimore, MD 21287, USA. jcarhua1@jhmi.edu
Abstract
BACKGROUND: Recent reports suggest that when thrombolytic agents are administered within the clot, lysis rate accelerates at the expense of increased risk of worsening edema. To test this hypothesis, we report on the volumetric analysis of (1) the intraparenchymal hematoma and, (2) perihematomal edema in a cohort of ICH patients treated with intraclot rtPA. METHODS: A convenience sample of highly selected ICH patients underwent frameless stereotactic aspiration and thrombolysis (FAST) of the clot. Two milligrams of rtPA were administered every 12 h until ICH volume < or =10 cc, or catheter fenestrations were no longer in continuity with the clot. ICH and perihematomal edema volumes were calculated from CT scans. Using random effects linear regression we estimated the rate of hematoma and edema volume resolution as well as their relationship during the first 8 days of lytic therapy. RESULTS: Fifteen patients were treated, mean age: 60.7 years, median time from ictus to FAST: 1 (range 0-3) day. Using a random effects model that considered volume resolution over the first 8 days following lytic therapy we found that the both percentage hematoma and percentage perihematoma edema resolution per day were quadratic with respect to time. Percentage residual hematoma volume on day K = 97.7% - [24.36%*K] + [1.89%*K (2)]; P < 0.001 for both terms. Percentage residual edema on day K = 97.4% - [13.94%*K] + [1.30%*K (2)]; P < 0.001 for K and P = 0.01 for K (2). Examination of each patient's volume data suggests that there exists a strong direct relationship between perihematoma edema volume and same day hematoma volume. CONCLUSIONS: In this cohort of ICH patients treated using FAST, volumetric analysis of ICH and perihematomal edema seems to suggest that local use of rtPA does not exacerbate brain edema formation. Furthermore, there seems to be a strong association between reduction in ICH volume and reduction in edema volume, as would be expected following the concept of "hemotoxicity" postulated by some investigators.
BACKGROUND: Recent reports suggest that when thrombolytic agents are administered within the clot, lysis rate accelerates at the expense of increased risk of worsening edema. To test this hypothesis, we report on the volumetric analysis of (1) the intraparenchymal hematoma and, (2) perihematomal edema in a cohort of ICHpatients treated with intraclot rtPA. METHODS: A convenience sample of highly selected ICHpatients underwent frameless stereotactic aspiration and thrombolysis (FAST) of the clot. Two milligrams of rtPA were administered every 12 h until ICH volume < or =10 cc, or catheter fenestrations were no longer in continuity with the clot. ICH and perihematomal edema volumes were calculated from CT scans. Using random effects linear regression we estimated the rate of hematoma and edema volume resolution as well as their relationship during the first 8 days of lytic therapy. RESULTS: Fifteen patients were treated, mean age: 60.7 years, median time from ictus to FAST: 1 (range 0-3) day. Using a random effects model that considered volume resolution over the first 8 days following lytic therapy we found that the both percentage hematoma and percentage perihematoma edema resolution per day were quadratic with respect to time. Percentage residual hematoma volume on day K = 97.7% - [24.36%*K] + [1.89%*K (2)]; P < 0.001 for both terms. Percentage residual edema on day K = 97.4% - [13.94%*K] + [1.30%*K (2)]; P < 0.001 for K and P = 0.01 for K (2). Examination of each patient's volume data suggests that there exists a strong direct relationship between perihematoma edema volume and same day hematoma volume. CONCLUSIONS: In this cohort of ICHpatients treated using FAST, volumetric analysis of ICH and perihematomal edema seems to suggest that local use of rtPA does not exacerbate brain edema formation. Furthermore, there seems to be a strong association between reduction in ICH volume and reduction in edema volume, as would be expected following the concept of "hemotoxicity" postulated by some investigators.
Authors: N J Naff; J R Carhuapoma; M A Williams; A Bhardwaj; J A Ulatowski; J Bederson; R Bullock; E Schmutzhard; B Pfausler; P M Keyl; S Tuhrim; D F Hanley Journal: Stroke Date: 2000-04 Impact factor: 7.914
Authors: Paul Vespa; David McArthur; Chad Miller; Kristine O'Phelan; John Frazee; Chelsea Kidwell; Jeffery Saver; Sidney Starkman; Neil Martin Journal: Neurocrit Care Date: 2005 Impact factor: 3.210
Authors: Ryan J Barrett; Rahat Hussain; William M Coplin; Samera Berry; Penelope M Keyl; Daniel F Hanley; Robert R Johnson; J Ricardo Carhuapoma Journal: Neurocrit Care Date: 2005 Impact factor: 3.210
Authors: Stephan A Mayer; Nikolai C Brun; Kamilla Begtrup; Joseph Broderick; Stephen Davis; Michael N Diringer; Brett E Skolnick; Thorsten Steiner Journal: N Engl J Med Date: 2005-02-24 Impact factor: 91.245
Authors: A David Mendelow; Barbara A Gregson; Helen M Fernandes; Gordon D Murray; Graham M Teasdale; D Terence Hope; Abbas Karimi; M Donald M Shaw; David H Barer Journal: Lancet Date: 2005 Jan 29-Feb 4 Impact factor: 79.321
Authors: Ruth Thiex; Wilhelm Küker; P Jungbluth; C Kayser; Harald D Müller; Ina Rohde; Joachim M Gilsbach; Veit Rohde Journal: Neurol Res Date: 2005-07 Impact factor: 2.448
Authors: David W Newell; M Mohsin Shah; Robert Wilcox; Douglas R Hansmann; Erik Melnychuk; John Muschelli; Daniel F Hanley Journal: J Neurosurg Date: 2011-06-10 Impact factor: 5.115
Authors: W Andrew Mould; J Ricardo Carhuapoma; John Muschelli; Karen Lane; Timothy C Morgan; Nichol A McBee; Amanda J Bistran-Hall; Natalie L Ullman; Paul Vespa; Neil A Martin; Issam Awad; Mario Zuccarello; Daniel F Hanley Journal: Stroke Date: 2013-02-07 Impact factor: 7.914
Authors: Wendy Ziai; Tom Moullaali; Saman Nekoovaght-Tak; Natalie Ullman; Jay S Brooks; Timothy C Morgan; Daniel F Hanley Journal: Neurocrit Care Date: 2013-06 Impact factor: 3.210